Our invention is a novel preservation fluid, a medical device which promotes protection of the graft and thus facilitates improved transplantation outcomes. By developing a novel solution containing Sigma-1 receptor agonists we aim to tackle the problem of donor shortage by optimizing the condition of expanded criteria donor grafts and extending maximum graft storage time.
More than 2 million patients are affected by end-stage renal disease worldwide; the number of patients increased tenfold in the past twenty years. The primary treatment option is kidney transplantation, which is associated with improved survival, quality of life and reduced costs compared to dialysis. However, donor organ shortage is a considerable problem and ischemia/reperfusion injury is a major complication that has special influence on long-term survival, yet therapeutic options are not sufficient.
Corneal transplantation is one of the most common types of transplantation with more than 150,000 cases worldwide each year. Despite improved success rate of surgeries 30% of cornea grafts get rejected. Several risk factors (age, comorbidities like diabetes, hypertension, inflammatory diseases, or previous graft rejection) could worsen outcomes. In addition, globally limited supply of donors is an increasing challenge that necessitates improvement of long-term graft preservation.